SENP1、SENP2和SENP6蛋白在人恶性胶质瘤组织和细胞中的表达及其意义

doi:10.13481/j.1671-587x.20190114

Abstract

Abstract: Objective: To observe the expressions of SENP1, SENP2 and SENP6 proteins in human malignant glioma tissue and cells, and to elucidate the their effects in the development of malignant glioma.Methods: The samples of normal human brain tissue and malignant glioma tissue were obtained and used as normal control group and malignant glioma group, respectively.The Cos7 cells and the malignant glioma LN443 and U343 cells were cultured;the Cos7 cells were used as normal cell control group,and the LN443 and U343 cells as malignant glioma cell group. Western blotting method was used to detect the expression levels of SENP1, SENP2 and SENP6 proteins in human malignant glioma tissue and cells.Results: In brain tissue, the expression levels of SENP1, SENP2 and SENP6 proteins in malignant glioma group were higher than those in normal control group(P<0.05). Compared with normal cell control group, the expression levels of SENP1, SENP2 and SENP6 proteins in the LN443 and U343 cells in malignant glioma cell group were significantly increased (P<0.05).Conclusion: SENP1, SENP2 and SENP6 proteins highly express in the malignant glioma tissue and cells, and they may play an important role in promoting the occurrence of malignant glioma.

Key words: SUMO-special proteases, malignant glioma, LN443 cell, U343 cell

CLC Number:

R739.41

WANG Dongdong, ZHANG Yu, ZHANG Weiqi, DING Zhendong, YU Hongquan, QI Ling. Expressions of SENP1, SENP2 and SENP6 proteins in human glioma tissue and cells and their mechanisms[J].Journal of Jilin University(Medicine Edition), 2019, 45(01): 73-76.

References

[1] PEEK J,HARVEY C,GRAY D, et al. SUMOtargeting of a stress-tolerant Ulp1 SUMO protease[J]. PLoS ONE, 2018, 13(1):e0191391.
[2] LIU K,ZHANG J,WANG H. Small ubiquitin-like modifier/sentrin-specific peptidase 1 associates with chemotherapy and is a risk factor for poor prognosis of non-small cell lung cancer[J]. J Clin Lab Anal, 2018, 32(9):e22611.
[3] DE ANDRADE J P,LORENZEN A W,WU V T, et al. Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer[J]. Oncotarget, 2017, 8(70):114801-114815.
[4] YANG Y,XIA Z,WANG X, et al. Small-molecule inhibitors targeting protein SUMOylation as novel anticancer compounds[J]. Mol Pharmacol, 2018, 94(2):885-894.
[5] 齐玲, 王玮瑶, 郑中华, 等. SUMO及SUMO化修饰蛋白在恶性胶质瘤发生中的作用[J]. 吉林大学学报:医学版, 2016, 42(1):7-10.
[6] DONG B,GAO Y,KANG X, et al. SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis[J]. Oncotarget, 2016,7(49):80435-80449.
[7] JIN Z L,PEI H,XU Y H,et al. The SUMO-specific protease SENP5 controls DNA damage response and promotes tumorigenesis in hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci,2016,20(17):3566-3573.
[8] MIRECKA A,MORAWIEC Z,WOZNIAK K. Genetic polymorphism of SUMO-Specific cysteine proteases-SENP1 and SENP2 in breast cancer[J]. Pathol Oncol Res, 2016, 22(4):817-823.
[9] JIANG Q F,TIAN Y W,SHEN Q, et al. SENP2 regulated the stability of β-catenin through WWOX in hepatocellular carcinoma cell[J]. Tumour Biol, 2014,35(10):9677-9682.
[10] 齐玲, 沈楠, 王玮瑶, 等. SENP蛋白在胶质瘤中表达与临床病理分级相关性[J]. 中国公共卫生, 2015, 31(9):1219-1221.
[11] WANG Q,XIA N,LI T, et al. SUMO-specific protease 1 promotes prostate cancer progression and metastasis[J]. Oncogene, 2013, 32(19):2493-2498.
[12] CHENG J,BAWA T,LEE P, et al. Role of desumoylation in the development of prostate cancer[J]. Neoplasia, 2006, 8(8):667-676.
[13] XU Y, ZUO Y, ZHANG H, et al. Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF expression and angiogenesis[J]. J Biol Chem, 2010, 285(47):36682-36688.
[14] WANG R T, ZHI X Y, ZHANG Y, et al. Inhibition of SENP1 induces radiosensitization in lung cancer cells[J]. Exp Ther Med, 2013, 6(4):1054-1058.
[15] ZHANG Q S, ZHANG M, HUANG X J, et al. Downregulation of SENP1 inhibits cell proliferation, migration and promotes apoptosis in human glioma cells[J]. Oncol Lett, 2016,12(1):217-221.
[16] MA C, WU B, HUANG X, et al. SUMO-specific protease 1 regulates pancreatic cancer cell proliferation and invasion by targeting MMP-9[J]. Tumour Biol, 2014, 35(12):12729-12735.
[17] TAN M Y, MU X Y, LIU B, et al. SUMO-specific protease 2 suppresses cell migration and invasion through inhibiting the expression of MMP13 in bladder cancer cells[J]. Cell Physiol Biochem, 2013,32(3):542-548.
[18] HU X Y, LIU Z, ZHANG K L, et al. SUMO-specific protease 2-mediated deSUMOylation is required for NDRG2 stabilization in gastric cancer cells[J]. Cancer Biomark, 2017, 21(1):195-201.
[19] SHEN H J, ZHU H Y, YANG C, et al. SENP2 regulates hepatocellular carcinoma cell growth by modulating the stability of beta-catenin[J]. Asian Pac J Cancer Prev,2012,13(8):3583-3587.
[20] FU J, YU H M, CHIU S Y, et al. Disruption of SUMO-specific protease 2 induces mitochondria mediated neurodegeneration[J]. PLoS Genet, 2014, 10(10):e1004579.
[21] QIAN J, LUO Y, GU X, et al. Inhibition of SENP6-induced radiosensitization of human hepatocellular carcinoma cells by blocking radiation-induced NF-kappaB activation[J]. Cancer Biother Radiopharm, 2013, 28(3):196-200.

Expressions of SENP1, SENP2 and SENP6 proteins in human glioma tissue and cells and their mechanisms

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 3

Metrics

Comments

Recommended 0

[1]	QI Ling, WANG Weiyao, ZHENG Zhonghua, ZHANG Yizhong, ZHAO Liwei, ZHONG Xiuhong, ZHAO Donghai, YANG Shuyan, YANG Ningjiang, REN Kuang, YU Hongquan. Effects of SUMO and proteins modified by SUMO on occurrence of malignant gliomas [J]. Journal of Jilin University Medicine Edition, 2016, 42(01): 7-10.
[2]	ZHANG Yu-yu,QU Ya-qin,JIANG Xin,ZHAO Qin,GUO Xiao,FENG Qi. Evaluation of short-term efficacy and safety of intensity modulated radiation therapy plus concomitant and adjuvant temozolomide in patients with malignant gliomas [J]. J4, 2012, 38(3): 571-574.
[3]	ZHANG Mao,JIN Hai-guo,SUN Shu-quan,BU Ming-wei,SU Qing-xiu,LIU Gui-gang,SUN Bao-. Detection of \|radiation brain injury of malignant glioma by 1H-MRS [J]. J4, 2011, 37(4): 742-745.